Insider trade

Officer purchased ~$863K of DXCM shares in the open market

Traded Nov 10, 2025 · Filed Nov 11, 2025

~$863K
Reported value · 16K sh @ $54.977: 329K
Holds after · shares reported: +57.2%
stock since the trade · S&P 500 +12.1%, $54.84 → $86.23 on Oct 1

Why it stands out

Dexcom's President & COO spent $863K of their very own money to buy Dexcom shares. Their pile of Dexcom shares grew by 5%.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 10, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 11, 2025

Officer$500K–$1MHoldings +5%

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$863,139

Shares × reported transaction price

Size band

$500K–$1M

Ownership change

+5.0%

Purchase shares ÷ estimated pre-transaction holdings, from the filing

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

No other insider purchases within 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals about 15% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2024 ($5.62M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-15. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

11 days after results of Oct 30, 2025, 63 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $54.84 on Nov 10, 2025, at its 52-week low, after a 17% drop over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $90.75 (Feb 24, 2025), 0% of the way up, from 250 adjusted closes. 30 trading days earlier: $66.46 on Sep 29, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Nov 10, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

5 such cases were open. Oakland County Employees Retirement System v. DexCom, Inc., docket 1:25-cv-09370, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.5%	-3.4%	+6.9%
30 days	+18.6%	+0.9%	+17.7%
90 days	+20.7%	+1.6%	+19.1%
180 days	+2.1%	+8.2%	-6.2%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-25-000284
Filed / recorded: Nov 11, 2025, 12:13 AM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Jacob Steven Leach
Relationship: Officer
Officer title: President & COO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 10, 2025
Transaction code: P
Shares / units: 15,700
Price per share: $54.977
Acquired / disposed: Acquired (A)
Shares owned after: 329,197
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $54.34 to $55.33. The price above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.